EUAA

Guardant360 CDx is the fastest CGP panel
with guideline-recommended biomarkers.^1-4*

The market leader in liquid biopsy,
backed by the strongest legacy in blood-based NGS.

First FDA-approved
comprehensive liquid biopsy
with results in 5 days^1,2,5*^†

For the complete intended use statement including companion diagnostic indications,
please see the Guardant360 CDx Technical Information: Guardant360CDx.com/technicalinfo.

Product availability may vary depending on region.

Certified & compliant

Trusted by more than
15,000 oncologists

CGP, comprehensive genomic profiling; NGS, next-generation sequencing.
*Of FDA-approved comprehensive liquid biopsies as of February 2024.
†Fastest median turnaround time from sample receipt to results based on stated turnaround times from Integra Connect data.

Next >

Home Oncology Portfolio Partnerships European Policy